To date, liquid biopsies have shown the selective pressure of anti-EGFR therapies in patients with RAS-wild-type * colorectal tumors, in that acquired resistance to EGFR blockade is often driven by the emergence of KRAS/NRAS mutations in plasma [18]. The gene discussed is KRAS; the disease is colorectal neoplasm.